In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Deals Shaping the Medical Industry (12/06)

Executive Summary

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

You may also be interested in...



Podcast: Diversity, Equity, and Inclusion Measures Continue to Evolve in the Clinical Space

Listen to expert perspectives from Tracey Parker, Vice President, Biometrics, Advanced Clinical and Rebecca Starkie, Senior Global Patient Engagement Director, Advanced Clinical on the recent history of DEI in clinical trials and the barriers to patient participation. Examine the key drivers that have influenced the development of diversity, equity, and inclusion programs for clinical trials.

US FDA Balances Urgent Need For Platinum Chemotherapies Against Intas Plant’s Quality Failures

As politicians demand help for cancer-ridden constituents, the agency allows Indian plant that flunked inspection to resume exporting batches of cisplatin and carboplatin to the US, but only after passing independent 45-day batch certification reviews.

BIO Notebook Day 4: Waiting On Data, Adjusting To The IRA, And Focusing On All Patients

GSK, BridgeBio, and the US FDA’s patient-focused drug development director discuss contingency planning as the BIO International Convention concludes in Boston.

Table

View full table

Related Companies

Tags:
Latest Headlines

BioBytes: Against A Turbulent Corporate Backdrop, Illumina Touts New AI Gene Analysis Tool

China’s Cancer Market Is Evolving Fast, Four Multinationals Dominate

Connecting The Dots Between Diversity, Empowerment And Business Growth

New Therapeutic Areas Ignite Investor Interest Amid Pandemic Reset

See All
UsernamePublicRestriction

Register

IV002693

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By